Cancer clinical trials in the region Centre-Val de Loire

114 currently recruiting clinical trials
Region Centre-Val de Loire

Phase 3 Cervical / Vulvar / Vaginal cancer #NCT07216703 #2025-521514-26-00
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required CPS scores
CPS Positive (>= 1)
Excluded previous treatments at localized stage
Systemic Treatment-Naive
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Amyloidosis #NCT07052903 #2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07218809 #2025-520466-22-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
AstraZeneca
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07318558
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Clear cell carcinoma
Required FIGO stages
Stage III Stage IV
Required disease stage
Localized
Required HRD statuses
HRD Negative
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Surgery Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Multiple myeloma #NCT07258511 #2025-522007-18-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
3 or more
Required previous treatments
Monoclonal antibodies Proteasome inhibitor Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
6 recruiting sites
Janssen
Phase 3 Lung cancer #NCT05899608 #2024-513087-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Summit Therapeutics
Phase 3 Skin cancer #NCT06692556
Required histologic types
Squamous cell carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Radiotherapy
12 recruiting sites
Centre Léon Bérard
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Small intestine and appendix cancer #NCT07087054 #2024-519875-24-00
Required histologic types
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06104566 #2023-508005-24-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
12 recruiting sites
Ascentage Pharma Group Inc.
Phase 3 Amyloidosis #NCT07207811 #2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S